79 related articles for article (PubMed ID: 24305533)
1. [Picture in clinical hematology no. 67].
Rinsho Ketsueki; 2013 Nov; 54(11):2023. PubMed ID: 24305533
[No Abstract] [Full Text] [Related]
2. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease.
Elstein D; Cohn GM; Wang N; Djordjevic M; Brutaru C; Zimran A
Blood Cells Mol Dis; 2011 Jan; 46(1):119-23. PubMed ID: 20727796
[TBL] [Abstract][Full Text] [Related]
3. Histologic findings of femoral heads from patients with Gaucher disease treated with enzyme replacement.
Lebel E; Elstein D; Peleg A; Reinus C; Zimran A; Amir G
Am J Clin Pathol; 2013 Jul; 140(1):91-6. PubMed ID: 23765538
[TBL] [Abstract][Full Text] [Related]
4. Gaucher disease.
Butters TD
Curr Opin Chem Biol; 2007 Aug; 11(4):412-8. PubMed ID: 17644022
[TBL] [Abstract][Full Text] [Related]
5. Hypothesis: Concordance of Gaucher disease and large granular lymphocytic leukemia has biological plausibility.
Ruchlemer R; Maayan H; Elstein D; Broide E; Reinus C; Zimran A
Blood Cells Mol Dis; 2014 Dec; 53(4):219-20. PubMed ID: 25053276
[No Abstract] [Full Text] [Related]
6. Novel heterozygous c.798C>G and c.1040T>G mutations in the GBA1 gene are associated with a severe phenotype of Gaucher disease type 1.
Machaczka M; Klimkowska M
Ann Hematol; 2014 Oct; 93(10):1787-9. PubMed ID: 24577513
[No Abstract] [Full Text] [Related]
7. Ambroxol improves skeletal and hematological manifestations on a child with Gaucher disease.
Jiang W; Yi M; Maegawa GHB; Zhang H
J Hum Genet; 2020 Mar; 65(3):345-349. PubMed ID: 31822786
[TBL] [Abstract][Full Text] [Related]
8. The uptake of recombinant glucocerebrosidases by blood monocytes from type 1 Gaucher disease patients is variable.
Berger J; Stirnemann J; Bourgne C; Pereira B; Pigeon P; Heraoui D; Froissart R; Rapatel C; Rose C; Belmatoug N; Berger MG
Br J Haematol; 2012 Apr; 157(2):274-7. PubMed ID: 22224474
[No Abstract] [Full Text] [Related]
9. Competing for the treasure in exceptions.
Cox TM
Am J Hematol; 2013 Mar; 88(3):163-5. PubMed ID: 23400870
[No Abstract] [Full Text] [Related]
10. A French experience of type 3 Gaucher disease: Phenotypic diversity and neurological outcome of 10 patients.
Kraoua I; Sedel F; Caillaud C; Froissart R; Stirnemann J; Chaurand G; Flodrops H; Tari S; Gourfinkel-An I; Mathieu S; Belmatoug N; Billette de Villemeur T; Mignot C
Brain Dev; 2011 Feb; 33(2):131-9. PubMed ID: 20307947
[TBL] [Abstract][Full Text] [Related]
11. Vitreous Changes in Gaucher Disease Type 3.
Promelle V; Salvarinova R; Lyons CJ
Ophthalmology; 2020 Jun; 127(6):813. PubMed ID: 32444021
[No Abstract] [Full Text] [Related]
12. Novel G377S (c.1246G>T) mutation associated with Gaucher disease type 1.
Zhou Y; Kraemer RR; Peker D; Wakefield DN; de Idiaquez Bakula DA
Am J Hematol; 2013 Oct; 88(10):922-3. PubMed ID: 23828321
[No Abstract] [Full Text] [Related]
13. Early access experience with VPRIV(®): recommendations for 'core data' collection.
Hughes DA; Al-Sayed M; Belmatoug N; Bodamer O; Böttcher T; Cappellini M; Cohen IJ; Eagleton T; Elstein D; Giraldo P; Jones S; Kaplinsky C; Lund A; Machaczka M; Mengel E; Pastores GM; Rosenbaum H; Sjo M; Tiling N; Tsaftaridis P; Zimran A; Weinreb N
Blood Cells Mol Dis; 2011 Aug; 47(2):140-2. PubMed ID: 21146428
[No Abstract] [Full Text] [Related]
14. Variant Gaucher disease characterized by dysmorphic features, absence of cardiovascular involvement, laryngospasm, and compound heterozygosity for a novel mutation (D409H/C16S).
Bodamer OA; Church HJ; Cooper A; Wraith JE; Scott CR; Scaglia F
Am J Med Genet; 2002 May; 109(4):328-31. PubMed ID: 11992489
[TBL] [Abstract][Full Text] [Related]
15. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
Gonzalez DE; Turkia HB; Lukina EA; Kisinovsky I; Dridi MF; Elstein D; Zahrieh D; Crombez E; Bhirangi K; Barton NW; Zimran A
Am J Hematol; 2013 Mar; 88(3):166-71. PubMed ID: 23386328
[TBL] [Abstract][Full Text] [Related]
16. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
Pastores GM
Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
[TBL] [Abstract][Full Text] [Related]
17. Assessment of quality of life in Gaucher disease: A methodological approach.
Zizemer VS; Nalin T; Schwartz IVD; Vanz AP
Mol Genet Genomic Med; 2021 Jan; 9(1):e1549. PubMed ID: 33220153
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel three-nucleotide insertion mutation (c.841-842insTGA) in the acid beta-glucosidase gene of a Taiwan Chinese patient with type II Gaucher disease.
Wu JY; Wu MC; Lee CC; Tsai FJ
Hum Mutat; 2001 Mar; 17(3):238. PubMed ID: 11241851
[No Abstract] [Full Text] [Related]
19. Type 2 gaucher disease: an expanding phenotype.
Tayebi N; Stone DL; Sidransky E
Mol Genet Metab; 1999 Oct; 68(2):209-19. PubMed ID: 10527671
[No Abstract] [Full Text] [Related]
20. [Gaucher's disease with D409H/D409H genotype. evolution with enzyme replacement therapy].
Castelló Girona F; Domínguez Luengo C; del Toro Riera M; Chabás Bergon A
An Esp Pediatr; 2001 Mar; 54(3):310-2. PubMed ID: 11262263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
